Aimike, which only sells hyaluronic acid, has doubled its profit and income in the first quarter.

Reporter | Zheng Jie

Edit | Xie Xin

On the evening of April 26, 2021, Amec announced its first quarter 2021 performance: operating income during the reporting period was approximately 259 million yuan, a year-on-year increase of 227.
52%; net profit during the reporting period was 172 million yuan, a year-on-year increase of 296.
50%; Non-net profit deducted was 162 million yuan, a year-on-year increase of 303.
31%
.

In a quarterly report, Amic said that the reason for the significant increase in performance is that the impact of the new crown epidemic on medical beauty consumption has been eliminated.
At the same time, "the advantage of the company's differentiated product layout is gradually showing.
" However, the current listed products of Amic Among them, the main growth point of its performance is the solution injection injection with Hibody as its core product.
According to its 2021 annual report, this type of product achieved operating income of 450 million yuan, an increase of 82.
85% over the same period last year
.

Relatively speaking, Amic’s gel injection products account for a decline in revenue.
According to its annual report, gel injection products will reach 252 million yuan in 2020, accounting for 35.
56% of revenue; and in 2019, gel injection products will account for 35.
56% of revenue.
Plastic injection products reached 312 million yuan, accounting for 55.
97% of revenue
.

        In fact, it is not so much that "differentiated product layout" drives performance, it is better to say that Hibody's precise positioning drives performance
.

        In fact, the industry has criticized the single structure of Amic's products before.
In the first quarterly report of Amic, Aphrodite, Bonita, etc.
are all hyaluronic acid products, and there is almost no other product line besides hyaluronic acid
.

        At present, in the domestic hyaluronic acid market, Amic has the largest market share among domestic companies, but the four foreign-funded companies LG of South Korea, Allergan of the United States, Humedix of South Korea, and Q-med of Sweden account for 70% of the market share.
In contrast, the market share of Amec is only about 10%
.

        Amico is known as the "Moutai of Medical Beauty" due to its high gross profit margin.
According to its financial report in the last three years (2018-2020), Amico's gross profit margin reached 89.
34%, 92.
63%, and 92.
17, respectively.
%; With the increase in gross profit margin, its net profit margin is also rising year by year
.

        However, the high gross profit of the hyaluronic acid industry is not limited to Aimeike.
The gross profit margin of Huaxi Biology’s main business has been maintained at a relatively high level in these years.
The gross profit margin of the main business in 2020 will exceed 80%.
Haohaishengke’s gross sales in 2020 The interest rate is 74.
93%.
Although it is the bottom of the three companies, it is also in the category of high gross profit
.

        Because of this, latecomers are also sharpening their swords and aiming at the hyaluronic acid and medical beauty markets, such as Huadong Medicine
.

        Relatively speaking, Amec pays more attention to independent research and development
.

        On April 13, 2020, Huadong Medicine announced that it had received the "Medical Device Registration Certificate" issued by the National Medical Products Administration.
The "Girls' Needle" will be officially launched in China in the second half of this year
.